Sparsentan

Unassigned

New Medicines

Focal segmental glomerulosclerosis

Information

New molecular entity
Retrophin
Retrophin

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Combined angiotensin receptor blocker and endothelin receptor type A blocker
Focal segmental glomerulosclerosis, or FSGS, is a rare disorder it is defined by progressive scarring of the kidney associated with proteinuria and often leads to end-stage renal disease and renal failure. In the absence of standard treatment, patients are treated with angiotensin receptor blockers, angiotensin converting enzyme inhibitors, calcineurin inhibitors, and steroids [1].
Focal segmental glomerulosclerosis
Oral